About US
Contact us
-
CDMO Fujifilm Diosynth's restructuring plan may leave up to 240 staffers out of workFujifilm Diosynth Biotechnologies'ventureinto separate small-scale and large-scale business units doesn't appear to be working out as planned. Tuesday, the CDMO revealed that it'sreworking its small-2024/4/11
-
Roche touts near-complete suppression of multiple sclerosis relapse for injectable OcrevusOne-year data continued to support a more convenient, injectable version of Roche’s blockbuster multiple sclerosis (MS) drug Ocrevus ahead of an FDA decision, the Swiss pharma said. A subcutaneous fo2024/4/9
-
Eli Lilly, plaintiffs agree to scrap $13.5M insulin pricing settlementAlmost a year after originally proposing a $13.5 million settlement to end years of litigation relating to alleged insulin overpricing, Eli Lilly and plaintiffs in the nationwide class-action lawsuit2024/4/9
-
With Vyvgart 'firing' in myasthenia gravis, argenx lays launch plans for next potential autoimmune approval: CEODespite a pair of clinical misfires in 2023, argenx has stuck by the thesis that its star drug Vyvgart, also known as efgartigimod, can tackle a wide array of autoimmune diseases linked to immunoglob2024/4/2
-
Eli Lilly inks deal to acquire Nexus manufacturing plant in Wisconsin as Mounjaro and Zepbound shortages drag onAs doctors and patients in the U.S. grapple with widening shortages of the popular diabetes therapy Mounjaro and its obesity counterpart Zepbound, the maker of the tirzepatide drugs, Eli Lilly, is fo2024/4/2
-
Another delay for Abeona's topical gene therapy pz-cel as FDA sends out a rejectionDating to a 2019clinical holdof a phase 3 trial, getting its gene therapy rademagene zamikeracel (pz-cel) across the FDA finish line has been a challenge for troubled Abeona Therapeutics. Now the wai2024/3/28
-
Novartis nominates former Bristol Myers CEO Giovanni Caforio as its new chair. Will M&A deals follow?Giovanni Caforio, M.D., is lining up a new gig soon after handing all his Bristol Myers Squibb leadership roles over in March. The recent Big Pharma CEO has been proposed as the new chair at Novartis2024/3/28
-
Despite positive trial, Roche says Enspryng fell short of expectations in myasthenia gravisDrug developers often try to spot tidbits of positive information from a failed clinical trial. But Roche is doing the opposite for its Enspryng study in the competitive autoimmune disorder of genera2024/3/25
-
GSK joins AstraZeneca, Boehringer in capping US out-of-pocket inhaler prices at $35 per monthAmid congressional scrutiny on U.S. inhaler prices, GSK is the latest pharma giantto commit to cappingpatients' monthly payments for itsportfolio of asthma and chronic obstructive pulmonary disease (2024/3/25
-
Merck’s Lynparza-Keytruda combo sputters in 2nd lung cancer trial. Will an ADC pairing work instead?Merck’s attempt to use Lynparza to boost Keytruda in metastatic non-small cell lung cancer has come up short with a second pivotal trial failure. Replacing the chemotherapy pemetrexed with Lynparza d2024/3/21